Description
The ADCC-enhanced antibody is a glycosylation-modified therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of fucosylation level. By reducing or removing the fucose of the Fc region, we obtained the ADCC-enhanced antibody, which showed increased binding affinity to the FcyR receptor on immune effector cells in an in vitro ADCC assay compared to its patent fucosylated antibody.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
MAb 4G7 is produced by using the human mammalian 293T cell line in the presence of the beta (1,4) -N-acetylglucosaminyltransferase III (GnTIII) enzyme, (1) at least 60% N-acetylglucosamine. Produced under conditions effective to produce Fc fragments in antibodies characterized by bisecting oligosaccharides and (2) Asn297-linked oligosaccharides containing only 10% non-fucosylated N-acetylglucosamine bisecting oligosaccharides It was.
Indication
Refractory B cell precursor Acute lymphoblastic leukemia
Relapsed B cell precursor Acute lymphoblastic leukemia
